title: In vitro activity of A-16686, a new glycopeptide.
abstract: A-16686 is a novel glycopeptide antibiotic derived from Actinoplanes. A-16686 inhibited hemolytic streptococci groups A, B, C, F, and G at concentrations of less than or equal to 0.06 to 0.5 microgram/ml, with 90% inhibited by 0.5 microgram/ml, including erythromycin-resistant isolates. S. bovis, various viridans groups streptococci, S. mitis, S. mutans, and S. sanguis were inhibited by less than or equal to 1 microgram/ml, and MICs of S. faecalis and S. faecium were 0.5-2 micrograms/ml. Most staphylococci, including methicillin-resistant strains, were inhibited by 1 or 2 micrograms/ml. A-16686 was bactericidal with minimal difference between MIC and MBC for gram-positive species. A-16686 did not inhibit Enterobacteriaceae or Pseudomonas.
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D047630:Depsipeptides; D006020:Glycopeptides / Q000494:pharmacology; D006088:Gram-Negative Aerobic Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D047630:Depsipeptides; D006020:Glycopeptides; D010456:Peptides, Cyclic; C041438:ramoplanin